A Window-of-opportunity Study of Pelareorep in Early Breast Cancer
NCT ID: NCT04102618
Last Updated: 2022-08-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
EARLY_PHASE1
26 participants
INTERVENTIONAL
2019-03-29
2022-04-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Olaparib in Locally Advanced ER, PgR and HER2 Negative (Triple Negative) and in Locally Advanced Germline BRCA Mutation-positive Breast Cancer Patients
NCT02681562
A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study
NCT04215146
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
NCT05104866
Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer
NCT00073528
A Study to Evaluate Erlotinib in Patients With Advanced or Metastatic Breast Cancer During or Following Chemotherapy
NCT00109265
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
After enrollment, pelareorep will be administered at 4.5 × 1010 TCID50 intravenously on days 1, 2, 8 \& 9. Other therapies will be administered according to the assigned treatment cohort.
After an initial biopsy (diagnostic biopsy in most cases), a second biopsy will be performed on Day 3. Patients will continue the planned treatment until day 21(±5), when a third biopsy will be performed. This third biopsy can be the surgical specimen if patient was scheduled for primary surgery, or a core biopsy if patient will undergo neoadjuvant treatment.
Blood samples will be collected throughout the study at three time points, Day 1, Day 3, and End of Treatment.
Patients will receive treatment for 3 weeks prior to surgery or neoadjuvant therapy. Thereafter, patients will either be considered for definitive surgery or primary medical treatment (e.g. neoadjuvant chemotherapy) at the discretion of the treating physician. Surgery or biopsy prior to neoadjuvant chemotherapy should be done within 3 weeks (±5 days) from the start of the study treatment.
The end of study visit will be performed at the day of surgery. A safety follow-up, the end of study visit, will be done at 28 days (± 7 days) after the last dose of treatment received
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort 1 (closed to enrollment)
HR+/HER2-neg patients who will receive pelareorep plus letrozole
Pelareorep
4.5 × 10e10 TCID50 administered intravenously on Days 1, 2, 8 \& 9
Letrozole
Oral dose of 2.5 mg/day starting on Day 3 for 13 days
Cohort 2 (closed to enrollment)
HR+/HER2-neg patients who will receive pelareorep plus letrozole plus atezolizumab
Pelareorep
4.5 × 10e10 TCID50 administered intravenously on Days 1, 2, 8 \& 9
Letrozole
Oral dose of 2.5 mg/day starting on Day 3 for 13 days
Atezolizumab
1200 mg administered intravenously on Day 3
Cohort 3 (closed to enrollment)
TNBC patients who will receive pelareorep plus atezolizumab
Pelareorep
4.5 × 10e10 TCID50 administered intravenously on Days 1, 2, 8 \& 9
Atezolizumab
1200 mg administered intravenously on Day 3
Cohort 4 (closed to enrollment)
HER2+/HR+ patients who will receive pelareorep plus trastuzumab plus atezolizumab
Pelareorep
4.5 × 10e10 TCID50 administered intravenously on Days 1, 2, 8 \& 9
Atezolizumab
1200 mg administered intravenously on Day 3
Trastuzumab
8mg/kg administered intravenously or 600mg subcutaneously on Day 3
Cohort 5 (closed to enrollment)
HER2+/HR- patients who will receive pelareorep plus trastuzumab plus atezolizumab
Pelareorep
4.5 × 10e10 TCID50 administered intravenously on Days 1, 2, 8 \& 9
Atezolizumab
1200 mg administered intravenously on Day 3
Trastuzumab
8mg/kg administered intravenously or 600mg subcutaneously on Day 3
Cohort 6
HER2+ (irrespective of HR status) (6 patients) who will receive pelareorep + trastuzumab
Pelareorep
4.5 × 10e10 TCID50 administered intravenously on Days 1, 2, 8 \& 9
Trastuzumab
8mg/kg administered intravenously or 600mg subcutaneously on Day 3
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pelareorep
4.5 × 10e10 TCID50 administered intravenously on Days 1, 2, 8 \& 9
Letrozole
Oral dose of 2.5 mg/day starting on Day 3 for 13 days
Atezolizumab
1200 mg administered intravenously on Day 3
Trastuzumab
8mg/kg administered intravenously or 600mg subcutaneously on Day 3
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Female patients.
3. Age ≥18 years. In cohorts 1 and 2 (patients with HR+/HER2 negative breast cancer), only postmenopausal\* patient can be included.
4. Histologically confirmed non-metastatic primary invasive adenocarcinoma of the breast, with all of the following characteristics:
* At least 1 lesion that can be measured in at least 1 dimension with ≥ 10 mm in largest diameter measured by ultrasound and mammogram.
* Documentation confirming the absence of distant metastasis (M0) as determined by institutional practice. Routine exams to discard metastases will be performed according to Investigator judgement but are mandatory in case of suspicion of metastatic disease.
* Breast cancer eligible for primary surgery.
* In the case of a multifocal tumor (defined as the presence of two or more foci of cancer within the same breast quadrant), the largest lesion must be ≥ 10 mm and designated the "target" lesion for all subsequent tumor evaluations and biopsies.
5. Patient must have biopsiable disease.
6. Histologically confirmed HER2 status and hormone receptors (ER and PgR) according to ASCO/CAP guidelines locally assessed.
* Invasive TNBC defined as: ER and PR negative defined as IHC nuclear staining \<1% AND HER2 negative.
* HR+/HER2 negative defined as: ER and PR positive defined as IHC nuclear staining \>1% AND HER 2 negatives.
* HER2 positive defined as; IHC +++ or FISH positive.
7. ECOG Performance Status of 0 or 1.
8. Adequate organ function, as determined by the following laboratory tests, within 14 days prior to randomization:
* Hematological
* Absolute neutrophil count (ANC) ≥ 1.5 x 109/L
* Platelet count ≥ 100 x 109/L
* Hemoglobin ≥ 9 g/dL (red blood cell transfusion and/or erythropoietin allowed)
* Renal
o Serum creatinine ≤ 1.5 x upper limit of normal (ULN), or 24-hour creatinine clearance ≥ 60 mL/min for subject with creatinine levels \> 1.5 x ULN. (Note: Creatinine clearance does not need to be determined if the baseline serum creatinine is within normal limits. Creatinine clearance should be calculated per institutional standard).
* Hepatic
* Serum bilirubin ≤ 1.5 x ULN OR direct bilirubin ≤ ULN for a subject with total bilirubin level \> 1.5 x ULN
* Aspartate aminotransferase (AST) ≤ 3 x ULN
* Alanine aminotransferase (ALT) ≤ 3 x ULN
* Coagulation International normalization ratio (INR) or prothrombin time (PT) ≤ 1.5 x ULN
* Partial thromboplastin time (PTT) or activated PTT (aPTT) ≤ 1.5 x ULN
9. Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial.
10. Female subject of childbearing potential should have a negative urine or serum pregnancy test within 72 hours prior to enrollment. If urine pregnancy test is positive or cannot be confirmed as negative, a serum pregnancy test will be required (only for cohorts 3 to 5 and pre-menopausal women or non-confirmed postmenopausal\* status).
* \*postmenopausal (defined as at least 12 months with no menses without an alternative medical cause; in women \< 45 years of age a high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy. In the absence of 12 months of amenorrhea, a single FSH measurement is insufficient.) OR
* have had a hysterectomy and/or bilateral oophorectomy, bilateral salpingectomy or bilateral tubal ligation/occlusion, at least 6 weeks prior to screening; OR
* has a congenital or acquired condition that prevents childbearing.
Exclusion Criteria
2. Metastatic (Stage IV) breast cancer.
3. Bilateral invasive breast cancer.
4. Multicentric breast cancer, defined as the presence of two or more foci of cancer in different quadrants of the same breast.
5. Prior therapy for breast cancer.
6. Prior therapy with an anti- PD-1, anti- PD-L1, anti-PD-L2, anti-CD137 antibody, or anti-CTLA-4 antibody compound, Pelareorep or any other oncolytic viruses.
7. Prior therapy with tumor vaccine
8. History or evidence of symptomatic autoimmune pneumonitis, glomerulonephritis, vasculitis, or other symptomatic autoimmune disease, or active autoimmune disease or syndrome that has required systemic treatment in the past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs) except vitiligo or resolved childhood asthma/atopy or evidence of clinically significant immunosuppression. Replacement therapy (i.e., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
9. Treated or untreated hyperthyroidism. Uncontrolled hypothyroidism (patients with controlled and asymptomatic hypothyroidism can be included)
10. Received any vaccine, including against SARS-COV-2 (COVID-19), \<14 days prior to the first day of study treatment. Inactivated vaccines (including against COVID-19 or seasonal influenza) are permitted after surgery.
11. History of other malignancy within the last 5 years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage I uterine cancer, or other malignancies with an expected curative outcome.
12. Evidence of clinically significant immunosuppression such as the following:
* diagnosis of immunodeficiency
* concurrent opportunistic infection
* receiving systemic immunosuppressive therapy (\> 2 weeks) or within 7 days prior to the first dose of study treatment, including oral steroid doses \> 10 mg/day of prednisone or equivalent. Subjects that require intermittent use of bronchodilators or local steroid injection will not be excluded from the study.
13. Cardiopulmonary dysfunction as defined by:
* Uncontrolled hypertension (systolic \>150 mm Hg and/or diastolic \> 100 mm Hg) despite optimal medical management.
* Inadequately controlled angina or serious cardiac arrhythmia not controlled by adequate medication.
* History of symptomatic congestive heart failure (CHF): Grade ≥ 3 per NCI CTCAE version 4.03 or Class ≥ II New York Health Association (NYHA criteria).
* Myocardial infarction within 6 months prior to randomization.
* Current dyspnea at rest due to complications of advanced malignancy, or other disease requiring continuous oxygen therapy
14. Current severe, uncontrolled systemic disease (e.g. clinically significant cardiovascular, pulmonary or metabolic disease; wound healing disorders; ulcers; bone fractures).
15. Major surgical procedure or significant traumatic injury within approximately 28 days prior to enrollment or anticipation of the need for major surgery during the course of study treatment.
16. Concurrent, serious, uncontrolled infections or current known infection with HIV or active hepatitis B and/or hepatitis C.
17. Assessment by the Investigator to be unable or unwilling to comply with the requirements of the protocol.
18. Known history of active Bacillus tuberculosis.
19. History of significant co-morbidities that, in the judgment of the Investigator, may interfere with the conduction of the study, the evaluation of response, or with informed consent.
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
SOLTI Breast Cancer Research Group
OTHER
Oncolytics Biotech
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
ICO Badalona
Badalona, , Spain
Hospital Clínic de Barcelona
Barcelona, , Spain
Hospital Quirón Dexeus
Barcelona, , Spain
Hospital Moisés Broggi
Esplugues de Llobregat, , Spain
Hospital Fuenlabrada
Madrid, , Spain
Hospital La Paz
Madrid, , Spain
Hospital Puerta de Hierro de Majadahonda
Madrid, , Spain
Hospital Universitario 12 de Octubre
Madrid, , Spain
Hospital Universitario Fundación Jiménez Díaz
Madrid, , Spain
Hospital Clínico Universitario Virgen Arrixaca
Murcia, , Spain
Hospital Universitario Virgen Macarena
Seville, , Spain
Hospital Clínico Universitario de Valencia
Valencia, , Spain
Instituto Valenciano de Oncología
Valencia, , Spain
Hospital Clínico Lozano Blesa
Zaragoza, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
REO 027
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.